STON1 Activators
Epidermal Growth Factor (EGF) interacts with its receptor to elevate endocytosis, potentially amplifying STON1's role at the cell membrane. In parallel, Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C, a pivotal player in the endocytic orchestra, which may enhance STON1-mediated activities. Pitstop 2, taking an alternative route, impedes clathrin-mediated endocytosis, possibly leading to a compensatory upregulation of STON1's function. Methyl-β-cyclodextrin (MβCD) extracts cholesterol from cell membranes, altering the intricate lipid environment that can affect STON1's membrane interactions. Dansylcadaverine and Chlorpromazine disrupt normal endocytic processes, with the potential to cause a rebalancing of STON1 activity to maintain cellular homeostasis.
Wortmannin, by inhibiting PI3K, and Genistein, by its broad-spectrum inhibition of tyrosine kinases, induce changes that can ripple through to STON1's operational pathways. Amiloride's inhibition of macropinocytosis might intersect with STON1's functional pathways, influencing its activity profile. The cytoskeleton-disrupting agents, Latrunculin A and Jasplakinolide, exert their effects by destabilizing or stabilizing actin filaments, respectively, which may affect the actin-dependent processes STON1 is associated with.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
A PKC activator that can stimulate endocytosis and potentially increase STON1 activity. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
An inhibitor of clathrin-mediated endocytosis that may indirectly increase STON1 activity by compensatory mechanisms. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A GTPase inhibitor that can disrupt dynamin function and may alter STON1-mediated endocytosis. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $20.00 $48.00 $160.00 $82.00 | 19 | |
Extracts cholesterol from membranes, possibly affecting STON1 interaction with lipid rafts and influencing its activity. | ||||||
Dansylcadaverine | 10121-91-2 | sc-214851 sc-214851A sc-214851B | 100 mg 250 mg 1 g | $52.00 $89.00 $240.00 | 4 | |
A transglutaminase inhibitor that can also label and inhibit endocytosis, potentially altering STON1 activity. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Blocks clathrin-mediated endocytosis, which may lead to compensatory changes in STON1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that affects endocytic pathways and could modulate the activity of STON1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A broad-spectrum tyrosine kinase inhibitor that can disrupt various signaling pathways, possibly affecting STON1’s function in endocytosis. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Can inhibit macropinocytosis and may have an impact on STON1’s role in endocytosis. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Disrupts actin polymerization and may affect STON1’s role in the actin-dependent endocytic pathway. | ||||||